Interferon gamma signaling
gene
reagent
sample publication
sample review
2 5 oligoadenylate synthetase like
2'-5'-oligoadenylate synthetase like
B2M
beta-2-microglobulin
total:5
Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. 2008 to the paper
Dako anti-B2m was used to perform immunohistochemistry in order to study the presence of specific populations of tumor infiltrating lymphocytes in diagnostic primary melanoma biopsies are associated with outcome in clinically stage II melanoma patients. more
CAMK2A
calcium/calmodulin dependent protein kinase II alpha
total:13
Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. 2009 to the paper
Affinity Bioreagents anti-phospho-CaMKII antibody was used for western blot in order to investigate the role of CaMKII in the regulation of pressure overload-induced cardiac hypertrophy to heart failure in mice. more
CAMK2D
calcium/calmodulin dependent protein kinase II delta
CAMK2G
calcium/calmodulin dependent protein kinase II gamma
total:10
Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2. 2010 to the paper
Santa Cruz anti-phos-CaMKII antibody was used to perform western blot in order to study the role of cGMP-dependent protein kinase and RGS2 in local antihypertrophic effects of cardiac atrial natriuretic peptide. more
CD44
CD44 molecule (Indian blood group)
total:49
Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. 2013 to the paper
Millipore rat anti-heparan sulfate proteoglycan monoclonal antibody was used to perform immunohistochemistry in order to investigate the role of sFLT-1 in the maintenance of the avascular photoreceptor layer in mouse models. more
CD56
neural cell adhesion molecule 1
total:56
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. 2012 to the paper
eBioscience anti-CD56 eFluor780 was used to perform flow cytometry in order to show that commensal bacteria was restricted in specific sites by innate lymphoid cells more
CD64
Fc fragment of IgG receptor Ia
total:15
PPAR? controls Dectin-1 expression required for host antifungal defense against Candida albicans. 2010 to the paper
Serotec anti-F4/80 antibody was used in flow cytometry in order to investigate the role of PPARgamma in the regulation dectin-1 expression and host antifungal defense. more
CIITA
class II major histocompatibility complex transactivator
total:5
A role for the JAK-STAT1 pathway in blocking replication of HSV-1 in dendritic cells and macrophages. 2009 to the paper
Biolegend anti-MHC class II-APC antibody was used in flow cytometry to harvest and stain infected cells in order to investigate the role of the JAK-STAT1 pathway in the regulation of the replication of HSV-1. more
DPB1
major histocompatibility complex, class II, DP beta 1
GBP 5
guanylate binding protein 5
total:1
GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. 2012 to the paper
SantaCruz goat-anti-human GBP5 was used to perform western blot in order to show that NLRP3 inflammasome could be regulated by GBP5 in mammals.
GBP1
guanylate binding protein 1
GBP2
guanylate binding protein 2
GBP3
guanylate binding protein 3
GBP4
guanylate binding protein 4
GBP6
guanylate binding protein family member 6
GBP7
guanylate binding protein 7
GILT
IFI30 lysosomal thiol reductase
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA E
major histocompatibility complex, class I, E
total:12
ESCRT-III governs the Aurora B-mediated abscission checkpoint through CHMP4C. 2012 to the paper
Serotec FITC-conjugated anti-MHC-I was used to perform flow cytometry in order to show that cell abscission mediated by Aurora B was regulated by ESCRT-III. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-DQA2
major histocompatibility complex, class II, DQ alpha 2
HLA-DQB1
major histocompatibility complex, class II, DQ beta 1
total:1
Expression of CD80 and CD86 costimulatory molecules are potential markers for better survival in nasopharyngeal carcinoma. 2007 to the paper
Novocastra Laboratories anti-HLA Class II (DR) was used to perform immunohistochemistry in order to show CD80 and CD86 may be potential nasopharyngeal carcinoma markers for clinical outcome.
HLA-DQB2
major histocompatibility complex, class II, DQ beta 2
total:1
Spontaneous lupus-like syndrome in HLA-DQ2 transgenic mice with a mixed genetic background. 2010 to the paper
Becton Dickinson anti-DQ (TU39) antibody was used to perform flow cytometry in order to investigate the role of HLA-DQ2 in the pathogenesis of associated immune disorders.
HLA-DR
major histocompatibility complex, class II, DR alpha
total:22
Tolerance induced via TLR2 and TLR4 in human dendritic cells: role of IRAK-1. 2008 to the paper
Beckman-Coulter anti-HLA DR- PC5 was used to perform flow cytometry in order to show that IRAK-1 blockade is important for tolerance of human DCs induced by TLR2 and TLR4 stimulation. more
HLA-DRB1
major histocompatibility complex, class II, DR beta 1
total:7
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. 2011 to the paper
Biolegend anti-HLADR was used in 2ug/ml to perform mass cytometry in order to show that different stimulation effect of human hematopoietic cells could be analysized by single-cell mass cytometry. more
HLA-DRB1
major histocompatibility complex, class II, DR beta 1
total:7
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. 2011 to the paper
Biolegend anti-HLADR was used in 2ug/ml to perform mass cytometry in order to show that different stimulation effect of human hematopoietic cells could be analysized by single-cell mass cytometry. more
HLA-DRB1
major histocompatibility complex, class II, DR beta 1
total:7
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. 2011 to the paper
Biolegend anti-HLADR was used in 2ug/ml to perform mass cytometry in order to show that different stimulation effect of human hematopoietic cells could be analysized by single-cell mass cytometry. more
HLA-DRB1
major histocompatibility complex, class II, DR beta 1
total:7
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. 2011 to the paper
Biolegend anti-HLADR was used in 2ug/ml to perform mass cytometry in order to show that different stimulation effect of human hematopoietic cells could be analysized by single-cell mass cytometry. more
HLA-DRB1
major histocompatibility complex, class II, DR beta 1
total:7
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. 2011 to the paper
Biolegend anti-HLADR was used in 2ug/ml to perform mass cytometry in order to show that different stimulation effect of human hematopoietic cells could be analysized by single-cell mass cytometry. more
HLA-DRB1
major histocompatibility complex, class II, DR beta 1
total:7
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. 2011 to the paper
Biolegend anti-HLADR was used in 2ug/ml to perform mass cytometry in order to show that different stimulation effect of human hematopoietic cells could be analysized by single-cell mass cytometry. more
HLA-DRB1
major histocompatibility complex, class II, DR beta 1
total:7
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. 2011 to the paper
Biolegend anti-HLADR was used in 2ug/ml to perform mass cytometry in order to show that different stimulation effect of human hematopoietic cells could be analysized by single-cell mass cytometry. more
HLA-DRB1
major histocompatibility complex, class II, DR beta 1
total:7
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. 2011 to the paper
Biolegend anti-HLADR was used in 2ug/ml to perform mass cytometry in order to show that different stimulation effect of human hematopoietic cells could be analysized by single-cell mass cytometry. more
HLA-DRB1
major histocompatibility complex, class II, DR beta 1
total:7
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. 2011 to the paper
Biolegend anti-HLADR was used in 2ug/ml to perform mass cytometry in order to show that different stimulation effect of human hematopoietic cells could be analysized by single-cell mass cytometry. more
HLA-DRB1
major histocompatibility complex, class II, DR beta 1
total:7
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. 2011 to the paper
Biolegend anti-HLADR was used in 2ug/ml to perform mass cytometry in order to show that different stimulation effect of human hematopoietic cells could be analysized by single-cell mass cytometry. more
HLA-DRB1
major histocompatibility complex, class II, DR beta 1
total:7
Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. 2011 to the paper
Biolegend anti-HLADR was used in 2ug/ml to perform mass cytometry in order to show that different stimulation effect of human hematopoietic cells could be analysized by single-cell mass cytometry. more
HLA-DRB3
major histocompatibility complex, class II, DR beta 3
HLA-DRB4
major histocompatibility complex, class II, DR beta 4
HLA-DRB4
major histocompatibility complex, class II, DR beta 4
HLA-DRB5
major histocompatibility complex, class II, DR beta 5
total:2
Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. 2008 to the paper
BD Pharmingen fluorochrome-conjugated HLA-DR antibody was used in flow cytometry in order to determine whether high LPS levels are associated with increased monocyte activation and HAD more
HLA-DRB5
major histocompatibility complex, class II, DR beta 5
total:2
Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. 2008 to the paper
BD Pharmingen fluorochrome-conjugated HLA-DR antibody was used in flow cytometry in order to determine whether high LPS levels are associated with increased monocyte activation and HAD more
HLA-F
major histocompatibility complex, class I, F
total:1
Progressive myopathy and defects in the maintenance of myotendinous junctions in mice that lack talin 1 in skeletal muscle. 2008 to the paper
Sigma mouse monoclonal MHCf antibody was used in immunohistochemistry in order to study the role of talin 1 in the development and function of skeletal muscle
ICAM-1
intercellular adhesion molecule 1
total:30
Remodelling of cortical actin where lytic granules dock at natural killer cell immune synapses revealed by super-resolution microscopy. 2011 to the paper
R&D systems anti-ICAM-1 antibody was used to perform immunocytochemistry in order to study the remodelling of cortical actin at natural killer cell immune synapses. more
IFN-gamma
interferon gamma
total:62
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. 2011 to the paper
R&D Systems anti-IFN-gamma was used in 5ug/ml to perform cell stimulation in order to show that blood-brain barrier integrity and CNS immune quiescence were promoted by sonic hedgehog pathway. more
IFNGR1
interferon gamma receptor 1
total:5
Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. 2008 to the paper
BD Biosciences anti-CD119 monoclonal antibody was used to perform flow cytometry in order to study the role of human BM-derived MSCs expressed TLR3 and TLR4 in inhibiting their T-Cell modulatory activity. more
IRF-1
interferon regulatory factor 1
total:14
Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. 2008 to the paper
Santa Cruz Biotechnology anti-IRF-1 antibody was used to perform western blot and immunohistochemical in order to study epstein-barr virus (EBV) infection of human B lymphocytes with interferon regulatory factor 4 (IRF-4). more
IRF-2
interferon regulatory factor 2
total:7
Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. 2008 to the paper
Santa Cruz Biotechnology anti-IRF-2 antibody was used to perform western blot and immunohistochemical in order to study epstein-barr virus (EBV) infection of human B lymphocytes with interferon regulatory factor 4 (IRF-4). more
IRF-3
interferon regulatory factor 3
total:22
DNA-PK is a DNA sensor for IRF-3-dependent innate immunity. 2012 to the paper
Life Technologies anti-IRF-3antibody was used to perform western blot in order to study IRF-3-dependent innate immunity more
IRF4
interferon regulatory factor 4
total:6
Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma. 2009 to the paper
Dako anti-MUM-1/IRF4 antibody (clone:MUM1P) was used in immunohistochemistry to analyze the expression pattern of MUM1, bcl-6, and CD138 along with the association of EBV in 222 well-characterized cases of BL. more
IRF5
interferon regulatory factor 5
total:1
Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression. 2010 to the paper
Abcam goat anti-IRF5 polyclonal antibody was used to perform immunoprecipitation in order to show that IRF5 mediated the transcriptional induction of proinflammatory cytokine expression in conjunction with HATs and HDACs.
IRF6
interferon regulatory factor 6
total:3
Human ?-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. 2012 to the paper
Difco anti-LPS was used to perform immunocytochemistry in order to show that mucosal innate immunity could be promoted by HD6 self-assembly. more
IRF7
interferon regulatory factor 7
total:4
Activation of anti-hepatitis C virus responses via Toll-like receptor 7. 2006 to the paper
Santa Cruz anti-IRF-7 antibody was used to perform western blot in order to study the mechanism of anti-HCV by TLR7 more
IRF8
interferon regulatory factor 8
total:4
IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways. 2006 to the paper
Santa Cruz Biotechnology anti-IRF-8 antibody was used in western blot to detect IRF-8 in RAW264.7 cells activated with IFN-gamma, LPS, PGN, and poly (I:C). more
IRF9
interferon regulatory factor 9
total:1
Sendai virus C protein plays a role in restricting PKR activation by limiting the generation of intracellular double-stranded RNA. 2008 to the paper
Santa Cruz Biotechnology anti-IRF9 antibody was used to perform western blot in order to show that SeV C protein can limit generation of dsRNA to restrict PKR activation.
Jak1
Janus kinase 1
total:22
Identification of human thioredoxin as a novel IFN-gamma-induced factor: mechanism of induction and its role in cytokine production. 2008 to the paper
Santa Cruz anti-Jak1 and anti-p-Jak1 were used to perform western blot in order to show that thioredoxin is an IFN-gamma-induced factor and plays a role for cytokine production. more
Jak2
Janus kinase 2
total:34
Covering a broad dynamic range: information processing at the erythropoietin receptor. 2010 to the paper
Upstate anti-JAK2 antibody was used to carry out immunoprecipitation assay and western blot analysis in order to determine the receptor property of erythropoietin receptor during receptor signaling activation. more
OAS1
2'-5'-oligoadenylate synthetase 1
total:2
A phylogenetically conserved RNA structure in the poliovirus open reading frame inhibits the antiviral endoribonuclease RNase L. 2007 to the paper
Abgent polyclonal rabbit antibodies against OAS1 were used to perform western blot in order to investigate the role of an RNA structure in the 3C protease ORF of poliovirus. more
OAS2
2'-5'-oligoadenylate synthetase 2
OAS3
2'-5'-oligoadenylate synthetase 3
PIAS1
protein inhibitor of activated STAT 1
total:3
Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone. 2006 to the paper
Santa Cruz Biotechnology anti-PIAS1(8152) antibody was used to perform western blot in order to study the process of cAMP signaling induced dynamic changes in the SUMO pathway determine the endometrial response to progesterone. more
PKC delta
protein kinase C delta
total:35
PKCalpha tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1. 2009 to the paper
Santa Cruz Biotechnology anti-PKCdelta antibody was used in western blot to study the mechanism underlying PKCalpha suppressing tumor in the intestine. more
platelet activating factor receptor
total:1
Relative levels of semen platelet activating factor-receptor (PAFr) and ubiquitin in yearling bulls with high content of semen white blood cells: implications for breeding soundness evaluation. 2007 to the paper
Cayman Chemicals PAF receptor antibody was used in western blot and immunohistochemistry to study the role of PAF receptor in fertility.
PML
promyelocytic leukemia
total:43
The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. 2010 to the paper
Santa Cruz Biotechnology anti-PMLwas used to perform immunocytochemistry in order to demonstrate that DAXX functions as a histone chaperone involved in the replication-independent deposition of H3.3. more
PTPN2
protein tyrosine phosphatase non-receptor type 2
total:2
MDA5 and PTPN2, two candidate genes for type 1 diabetes, modify pancreatic beta-cell responses to the viral by-product double-stranded RNA. 2010 to the paper
R&D Systems anti-PTPN2 antibody was used for western blot in order to investigate the roles of MDA5 and PTPN2 in the regulation of pancreatic cell responses to the viral by-product double-stranded RNA. more
SHP-1
protein tyrosine phosphatase non-receptor type 6
total:16
The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo. 2009 to the paper
Santa Cruz Biotechnology anti-SHP-1 polyclonal antibody was used in western blot in order to demonstrate that Lyn can inhibit osteoclast formation. more
SHP-2
protein tyrosine phosphatase non-receptor type 11
total:34
Autoamplification of Notch signaling in macrophages by TLR-induced and RBP-J-dependent induction of Jagged1. 2010 to the paper
Santa Cruz Biotechnology polyclonal anti-Shp2 antibody was used to perform western blot in order to study Notch signaling auto-amplification in macrophages which was regulated by TLR and RBP-J. more
SOCS3
suppressor of cytokine signaling 3
total:10
Unique early gene expression patterns in human adult-to-adult living donor liver grafts compared to deceased donor grafts. 2009 to the paper
Santa Cruz Biotech SOCS3 antibody was used in immunohistochemistry to study the distinctive differences at the molecular level between deceased donor (DD) and living donor (LD) liver grafts more
SP100
SP100 nuclear antigen
total:4
Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins. 2009 to the paper
Millipore anti-Sp100 antibody was used to perform immunohistochemistry in order to study the function of HP1 proteins in the alternative lengthening of telomeres-associated PML bodies by p53/p21. more
STAT1
signal transducer and activator of transcription 1
total:84
T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. 2010 to the paper
Santa Cruz Biotechnology anti-STAT1 polyclonal antibody was used to perform immunohistochemistry in order to study the transcriptional features of T-cell/histiocyte-rich large B-cell lymphoma. more
SUMO-1
small ubiquitin like modifier 1
total:40
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. 2012 to the paper
Abcam anti-SUMO1 was used to perform western blot in order to show that Myc-dependent cancer needs SUMOylation for tumorigenesis. more
VCAM-1
vascular cell adhesion molecule 1
total:19
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. 2009 to the paper
Immunotech anti-VCAM-1 antibody was used in blocking or activating expriments to study the role for prostate specific membrane antigen in regulating the expression of IL-6 and CCL5 in prostate tumour cells. more